This New Molecule Could Be Key to Treating Inflammatory Bowel Disease and Atopic Dermatitis
The molecule, DPT0218, was detected during preclinical animal trials.
inflamed bowels © freshidea - stock.adobe.com
DP Technology today announced the nomination of DPT0218, a novel small molecule targeting the potassium voltage-gated channel Kv1.3, as a preclinical candidate compound for the treatment of autoimmune diseases including atopic dermatitis (AD) and inflammatory bowel disease (IBD).1
The potassium channel Kv1.3 (also known as KCNA3) plays an essential role in T-cell proliferation and activation as well as cytokine production,2 and is crucial for maintaining the membrane potential required for the induction of inflammatory responses, according to DP Technology.
The molecule DPT0218 is a gut-restricted, highly potent and selective Kv1.3 inhibitor, with “best-in-class" potential and a novel scaffold, according to the company. It has shown positive results in preclinical animal models of various autoimmune diseases such as IBD and AD, it reported, and has an excellent safety profile.
"Although antibodies play a pivotal role in the treatment of moderate to severe IBD, their applications are limited by constrained therapeutic efficacy, immunogenicity, parenteral route of drug delivery, poor tolerability, and high cost." said Xiaomin Zhang, head of drug discovery at DP Technology, in a company press release.
"As a small molecule, DPT0218 has shown potent inhibition of T-cell activation, proliferation, and cytokine secretion in both in vivo and in vitro studies, demonstrating its potential as an effective treatment for IBD. We'll actively advance DPT0218 to clinical research and explore its application to other autoimmune diseases."
References
1. DP Technology Announces Nomination of Development Candidate, a Potential Best-in-Class Kv1.3 Inhibitor for Immunological Diseases Including IBD and AD. DP Technology. News release. January 30, 2924. Accessed January 30, 2024.https://www.prnewswire.com/news-releases/dp-technology-announces-nomination-of-development-candidate-a-potential-best-in-class-kv1-3-inhibitor-for-immunological-diseases-including-ibd-and-ad-302047637.html
2. National Center for Biotechnology Information. KCNA3 potassium voltage-gated channel subfamily A member 3 [Homo sapiens (human)]. National Library of Medicine. Updated November 23. 2023. Accessed January 30, 2024.https://www.ncbi.nlm.nih.gov/gene/3738
This article was originally posted in Dermatology Times.
Why Better Data and Awareness Matter for Medicaid Work Requirements
April 17th 2025With policymakers considering work requirements for Medicaid eligibility, Jennifer Haley, principal research associate in the Health Policy Division at the Urban Institute, said it’s more important than ever to understand how those changes could unintentionally cause harm, particularly when data systems fall short and public awareness is limited.
Read More
Insights Into Chronic Itch From Shawn Kwatra, M.D.
April 15th 2025A Q&A between Shawn Kwatra, M.D., professor and chair of dermatology at the University of Maryland School of Medicine, and Managed Healthcare Executive about new discoveries in chronic itch, how treatment options are improving and the challenges patients face in getting access to the right therapies.
Read More
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
